Phase 3
Completed N=239
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Source: ClinicalTrials.gov NCT00483652 ↗Enrolled (actual)
239
Serious AEs
3.4%
Results posted
Apr 2011
Primary outcomePrimary: Responders Based Upon the Timed 25-Foot Walk [T25FW] — 51; 11 participants
Summary
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Responders Based Upon the Timed 25-Foot Walk [T25FW] |
51; 11 | — |
| SECONDARY Change in Lower Extremity Manual Muscle Test [LEMMT] |
0.09; 0.04 | — |
Eligibility Criteria
Inclusion Criteria
- Patient with clinically defined multiple sclerosis
- All patients must be able to complete two trials of a timed 25 foot walk
Exclusion Criteria
- Female patients who are either pregnant or breastfeeding.
Data sourced from ClinicalTrials.gov (NCT00483652). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.